[{"orgOrder":0,"company":"Celerion","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PORT-77","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ALXN2080","moa":"Complement factor D (CFD)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Concert Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicopan","moa":"Complement factor D","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BBP-711","moa":"2-Hydroxyacid oxidase 1 (HAO1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALXN2050","moa":"Complement factor B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil HBr","moa":"PBP","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Oppilan Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NO-13065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexza Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZ-010","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Arthrosi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"14-C AR882","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"2217LS","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"}]
Find Clinical Drug Pipeline Developments & Deals by Celerion
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
